Терапия ожирения: влияние Орлистата (Ксеникал) на кардиометаболические факторы риска

1. Curran M., Scott L. Orlistat. A review of its use in the managements of patients with obesity. Drugs 2004; 64(24): 2845-64.

2. Despres J-P., Poirier P., Bergeron J. et al. From individual risk factors and the metabolic syndrome to global cardiometabolic risk. European Heart Journal 2008;10 ( suppl B): B24-B33.

3. Hutton B., Fergusson D. Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials. Am J Clin Nutr 2004; 80: 1461-8.

4. Kelley D., Bray G., Pi-Sunyer F. et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a1-year randomized controlled trial. Diab Care 2002;25: 1033-41.

5. O'Meara S., Riemsma R., Shirran L. et al. A systematic review of clinical effectiveness of orlistat used for management of obesity. Obes Rev 2004; 5: 51-68.

6. Shi Y., Pan C., Gao Y. Orlistat in the treatment of overweight or obese Chinese patients with newly diagnosed type 2 diabetes. 2005; 22: 2-8.

7. Swinburn B., Carey D., Hills A. et al. Effect of orlistat on cardiovascular disease risk in obese adults. Diab Obes Metab 2005; 7: 254-62.

8. Toplak H., Ziegler O., Keller U. et al. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet. Early response to treatment predicts weight maintenance. Diab Obes Metab.2005; 7: 699-706.

9. Torgerson J., Hauptman J., Boldrin M., Sjostrom L. XENical in the prevention of diabetes subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type2 diabetes in obese patients. Diab Care 2004; 27: 155-161.

10. Wirth A. Reduction of body weight and co-morbidities by orlistat: The XXL - Primary Health Care Trial. Diab Obes Metab 2005;7: 21-7.